Skip To Main Content
Yingyu Yu on Muck Rack

Yingyu Yu

As seen in: Frontiers
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingyu

Contact Yingyu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Age-stratified adverse-event reporting signals of seven ALK/ROS1 tyrosine kinase inhibitors in FAERS: a disproportionality and time to onset study

|
By Yongjian Liu, Xingjun Huang, Hao Zhong, Yingyu Yu, Yige Yu
| Frontiers
Abstract Background: ALK/ROS1 tyrosine kinase inhibitors (TKIs) have improved outcomes in molecularly selected malignancies, but trial populations do not fully represent the age and clinical heterogeneity encountered in routine care. Comparative post-marketing evidence on age-related and drug-specific reporting patterns remains limited. Methods: We analyzed US Food and Drug Administration Adverse Event Reporting System data from 2004 Q1 through 2026 Q1.
Open in Who Shared Issue with article?
See all 1 articles